139 related articles for article (PubMed ID: 8505638)
1. No evidence for altered muscle mitochondrial function in Parkinson's disease.
Anderson JJ; Bravi D; Ferrari R; Davis TL; Baronti F; Chase TN; Dagani F
J Neurol Neurosurg Psychiatry; 1993 May; 56(5):477-80. PubMed ID: 8505638
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial complex I deficiency in Parkinson's disease.
Schapira AH; Cooper JM; Dexter D; Clark JB; Jenner P; Marsden CD
J Neurochem; 1990 Mar; 54(3):823-7. PubMed ID: 2154550
[TBL] [Abstract][Full Text] [Related]
3. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy.
Blin O; Desnuelle C; Rascol O; Borg M; Peyro Saint Paul H; Azulay JP; Billé F; Figarella D; Coulom F; Pellissier JF
J Neurol Sci; 1994 Aug; 125(1):95-101. PubMed ID: 7964895
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson's Disease Research Group.
Schapira AH; Mann VM; Cooper JM; Krige D; Jenner PJ; Marsden CD
Ann Neurol; 1992; 32 Suppl():S116-24. PubMed ID: 1510369
[TBL] [Abstract][Full Text] [Related]
6. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
[TBL] [Abstract][Full Text] [Related]
7. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
8. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
[TBL] [Abstract][Full Text] [Related]
9. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.
Mann VM; Cooper JM; Krige D; Daniel SE; Schapira AH; Marsden CD
Brain; 1992 Apr; 115 ( Pt 2)():333-42. PubMed ID: 1606472
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease.
Hattori N; Tanaka M; Ozawa T; Mizuno Y
Ann Neurol; 1991 Oct; 30(4):563-71. PubMed ID: 1665052
[TBL] [Abstract][Full Text] [Related]
11. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease.
Bindoff LA; Birch-Machin MA; Cartlidge NE; Parker WD; Turnbull DM
J Neurol Sci; 1991 Aug; 104(2):203-8. PubMed ID: 1658241
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
13. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
14. Neurotoxicity and neuroprotection in Parkinson's disease.
Lange KW; Youdim MB; Riederer P
J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial respiratory chain function in multiple system atrophy.
Gu M; Gash MT; Cooper JM; Wenning GK; Daniel SE; Quinn NP; Marsden CD; Schapira AH
Mov Disord; 1997 May; 12(3):418-22. PubMed ID: 9159739
[TBL] [Abstract][Full Text] [Related]
16. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Bravi D; Anderson JJ; Dagani F; Davis TL; Ferrari R; Gillespie M; Chase TN
Mov Disord; 1992; 7(3):228-31. PubMed ID: 1620140
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Susceptibility Mapping in Parkinson's Disease.
Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport. Fatal infantile lactic acidosis and hypermetabolism with skeletal-cardiac myopathy and encephalopathy.
Hoppel CL; Kerr DS; Dahms B; Roessmann U
J Clin Invest; 1987 Jul; 80(1):71-7. PubMed ID: 3110216
[TBL] [Abstract][Full Text] [Related]
19. Evidence for mitochondrial dysfunction in Parkinson's disease--a critical appraisal.
Schapira AH
Mov Disord; 1994 Mar; 9(2):125-38. PubMed ID: 8196673
[TBL] [Abstract][Full Text] [Related]
20. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease.
Janetzky B; Hauck S; Youdim MB; Riederer P; Jellinger K; Pantucek F; Zöchling R; Boissl KW; Reichmann H
Neurosci Lett; 1994 Mar; 169(1-2):126-8. PubMed ID: 8047266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
